Disc Medicine Statistics
Total Valuation
Disc Medicine has a market cap or net worth of $2.92 billion. The enterprise value is $2.33 billion.
Important Dates
The next estimated earnings date is Thursday, February 26, 2026, before market open.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Disc Medicine has 37.75 million shares outstanding. The number of shares has increased by 27.33% in one year.
| Current Share Class | 37.75M |
| Shares Outstanding | 37.75M |
| Shares Change (YoY) | +27.33% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | 1.02% |
| Owned by Institutions (%) | 90.09% |
| Float | 32.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.72 |
| P/TBV Ratio | 5.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 23.45, with a Debt / Equity ratio of 0.05.
| Current Ratio | 23.45 |
| Quick Ratio | 23.03 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -61.77 |
Financial Efficiency
Return on equity (ROE) is -34.78% and return on invested capital (ROIC) is -23.69%.
| Return on Equity (ROE) | -34.78% |
| Return on Assets (ROA) | -22.61% |
| Return on Invested Capital (ROIC) | -23.69% |
| Return on Capital Employed (ROCE) | -33.73% |
| Weighted Average Cost of Capital (WACC) | 18.33% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.28M |
| Employee Count | 142 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Disc Medicine has paid $449,000 in taxes.
| Income Tax | 449,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +38.37% in the last 52 weeks. The beta is 2.58, so Disc Medicine's price volatility has been higher than the market average.
| Beta (5Y) | 2.58 |
| 52-Week Price Change | +38.37% |
| 50-Day Moving Average | 84.05 |
| 200-Day Moving Average | 66.32 |
| Relative Strength Index (RSI) | 46.55 |
| Average Volume (20 Days) | 526,251 |
Short Selling Information
The latest short interest is 4.28 million, so 11.34% of the outstanding shares have been sold short.
| Short Interest | 4.28M |
| Short Previous Month | 3.79M |
| Short % of Shares Out | 11.34% |
| Short % of Float | 13.25% |
| Short Ratio (days to cover) | 6.16 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -203.60M |
| Pretax Income | -180.66M |
| Net Income | -181.11M |
| EBITDA | -203.40M |
| EBIT | -203.60M |
| Earnings Per Share (EPS) | -$5.42 |
Full Income StatementBalance Sheet
The company has $615.92 million in cash and $30.98 million in debt, with a net cash position of $584.94 million or $15.50 per share.
| Cash & Cash Equivalents | 615.92M |
| Total Debt | 30.98M |
| Net Cash | 584.94M |
| Net Cash Per Share | $15.50 |
| Equity (Book Value) | 573.39M |
| Book Value Per Share | 16.38 |
| Working Capital | 600.42M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$164.67 million and capital expenditures -$1.36 million, giving a free cash flow of -$166.03 million.
| Operating Cash Flow | -164.67M |
| Capital Expenditures | -1.36M |
| Free Cash Flow | -166.03M |
| FCF Per Share | -$4.40 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Disc Medicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.33% |
| Shareholder Yield | -27.33% |
| Earnings Yield | -6.20% |
| FCF Yield | -5.69% |
Analyst Forecast
The average price target for Disc Medicine is $110.08, which is 42.37% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $110.08 |
| Price Target Difference | 42.37% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
